Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Classical hematology 1Breast 1

Conditions

Thrombocytopenia 1Neutropenia 1Neoplasms 1Genital Neoplasms, Female 1Colorectal Neoplasms 1Breast Neoplasms 1Anemia 1

Interventions

eltrombopag 14romiplostim 7avatrombopag 7Platelet Transfusion 6Cytarabine 6Radiotherapy 4Filgrastim 4Etoposide 4Carboplatin 4oprelvekin 3Tranexamic Acid 3Peripheral Blood Stem Cell Transplantation 3Daunorubicin 3Cyclophosphamide 3Busulfan 3hetrombopag 2fludarabine phosphate 2Tretinoin 2Thrombopoietin 2Lenalidomide 2Interleukin-11 2Ifosfamide 2Granulocyte Colony-Stimulating Factor 2Doxorubicin 2Cyclosporine 2Amplified Fragment Length Polymorphism Analysis 211-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 2sodium thiosulfate 1siltuximab 1sargramostim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thrombocytopenia × Moxibustion × Classical hematology × Clear all
NCT02781155 2016-05-24

Limiting Chemotherapy Side Effects by Using Moxa

East and North Hertfordshire NHS Trust

Phase 1/2 Unknown
25 enrolled
BreastClassical hematologyGastrointestinal

Anemia, Breast Neoplasms, Genital Neoplasms, Female, Neoplasms, Neutropenia, Thrombocytopenia, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡